Since TRPV1 expression is increased in IBD and its activation leads to SP and CGRP release triggering neurogenic inflammation, icilin-mediated blockade of TRPV1 function may be beneficial for IBD therapy in humans. The gene discussed is CALCA; the disease is inflammatory bowel disease.